Prescribing outside the licensed indications and doses constitutes off-label use, which requires prescribers to document their rationale, obtain informed consent, and provide appropriate monitoring
Observations with GLP-1 Agonists: Antibody Reduction: The speaker has witnessed significant reductions in Hashimoto's antibodies among patients using GLP-1agonists, indicating their potential role in managing auto-immune thyroid conditions
GLP-1 , 2 GLP-1 7 Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [15], Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) [16], Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) [17], EXenatide Study of Cardiovascular Event Lowering (EXSCEL) [18], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [19], Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [20], Peptide Innovation for Early Diabetes Treatment (PIONEER 6) [21] GLP-1
Emax was the inter-study variability of E max
The same compound is available in a lyophilized vial format elsewhere in the catalog for setups that prefer it